Cancer therapy articles from across Nature Portfolio

Early clinical data on in vivo CAR-T cell therapy for multiple myeloma reveals key mechanistic insights and could mark the beginning of a new era of fast, streamlined and accessible immunotherapies.

NRF2 enables tumor cells to tolerate oxidative and metabolic stress. A covalent molecular glue restores degradation of NRF2 by stabilizing the KEAP1–ubiquitin ligase complex.

We developed a nanoadjuvant platform that targets early endosome membranes in tumour cells, triggering their pyroptosis and the release of pyroptosomes, which act as an in situ vaccine against the tumour. In preclinical cancer models featuring multiple metastases, this nanoplatform enabled spatiotemporal induction of robust immune responses, resulting in systemic tumour eradication and long-lasting antitumour immunity.

Abumanhal-Masarweh et al. profile plasma proteomes of cancer patients during radiotherapy and detect acute changes in inflammatory and immune pathways. Correlating these changes with toxicity data enables identification of a predictive signature for radiation-induced toxicities.

Standard of care CD19-targeting CAR-T therapy for Relapsed-Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) faces frequent resistance often driven by regulatory T cell (Treg) activation. This study identifies Timosaponin AIII (TAIII) as A2AR inhibitor for enhanced CAR-T activity while depleting CAR-Treg formation.

In this Journal Club, Terrazas and Peón discuss a study that identifies a recurrent CTNNB1 mutation that generates shared neoantigens amenable to engineered T cell receptor (TCR)-T cell recognition. The work demonstrates potent antitumour activity across models and highlights the potential of targeting public mutations to broaden TCR-T cell immunotherapy for solid tumours.

Preclinical findings indicate that vamifeport, an oral ferroportin inhibitor, could be used as an adjunct therapy for lupus nephritis.

Early clinical data on in vivo CAR-T cell therapy for multiple myeloma reveals key mechanistic insights and could mark the beginning of a new era of fast, streamlined and accessible immunotherapies.

The small molecule rezatapopt binds a unique pocket in Y220C-mutant p53 and restores its tumor-suppressor function; a phase 1 study provides proof of concept of this therapeutic approach.